Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
2019 ◽
Vol 21
(10)
◽
pp. 1270-1278
◽
2019 ◽
Vol 27
(3)
◽
pp. 992-1001
◽
2020 ◽
Vol 39
(9)
◽
pp. 517-541